Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63

Benzinga Newsdesk www.benzinga.com Negative 66.4%

Neg 66.4% Neu 0% Pos 0%

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $65 to $63.